BioNTech SE
BNT327 Dose Level 1 (DL1)
Extensive-stage Small-cell Lung Cancer
Countdown
358days
Phase 2 readout · ~ Jun 30, 2027 estimated
What's at stake
Phase 2 trial results for BNT327 Dose Level 1 (DL1) in Extensive-stage Small-cell Lung Cancer are due ~ Jun 30, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT06449209: Phase 2 trial, sponsor BioNTech SE, drug BNT327 Dose Level 1 (DL1). Primary completion date 2027-06 (estimated).”